Microbicide Trial “Condom Only”-Arm Designs To Be Reviewed By FDA Cmte.
This article was originally published in The Tan Sheet
Executive Summary
FDA is seeking guidance from the Antiviral Drugs Advisory Committee as to whether clinical trials on topical microbicides should include a "no treatment" (condom only) arm
You may also be interested in...
Microbicide Trial Design Flexibility Supported At FDA Advisory Panel Meeting
Microbicide researchers and health advocates urged FDA to adopt a flexible approach to the design of clinical studies on products for reducing HIV transmission during an August 20 meeting of the agency's Antiviral Drugs Advisory Committee in Bethesda, Md
Microbicide Trial Three-Arm Design May Be Optimal Initially – Panelists
A microbicide clinical trial "win" should be based on "compelling" evidence of superior efficacy versus placebo and "supportive" evidence compared with a no-treatment arm, FDA Antiviral Drugs Advisory Committee consultant Richard Haubrich, MD, University of California, San Diego, said at an Aug. 20 meeting of the panel
Microbicide Trial Design Flexibility Supported At FDA Advisory Panel Meeting
Microbicide researchers and health advocates urged FDA to adopt a flexible approach to the design of clinical studies on products for reducing HIV transmission during an August 20 meeting of the agency's Antiviral Drugs Advisory Committee in Bethesda, Md